1. 5 Androsten 3 Beta Hydroxy 17 One
2. 5 Androsten 3 Ol 17 One
3. 5-androsten-3-beta-hydroxy-17-one
4. 5-androsten-3-ol-17-one
5. Androstenolone
6. Dehydroisoandrosterone
7. Dhea
8. Prasterone
9. Prasterone, 3 Alpha Isomer
10. Prasterone, 3 Alpha-isomer
1. Dhea
2. Prasterone
3. 53-43-0
4. Dehydroisoandrosterone
5. Androstenolone
6. Trans-dehydroandrosterone
7. Psicosterone
8. Diandron
9. Diandrone
10. 3beta-hydroxyandrost-5-en-17-one
11. 17-hormoforin
12. Prestara
13. 17-chetovis
14. Andrestenol
15. Intrarosa
16. 5-dehydroepiandrosterone
17. 3-beta-hydroxy-5-androsten-17-one
18. Dehydro-epi-androsterone
19. Siscelar Plus
20. (+)-dehydroisoandrosterone
21. 5,6-didehydroisoandrosterone
22. Dehydroepiandrosterone (dhea)
23. Prasteronum
24. 5,6-dehydroisoandrosterone
25. Astenile
26. Prasterona
27. Vaginorm
28. Epiandrosterone, 5-dehydro-
29. Caswell No. 051f
30. 5,6-dehydroisoandrostorone
31. 3beta-hydroxy-5-androsten-17-one
32. Biolaif
33. Ccris 3277
34. Deandros
35. 5-androsten-3beta-ol-17-one
36. (3-beta)-3-hydroxyandrost-5-en-17-one
37. Dehydroisoandosterone
38. Em-760
39. Gl 701
40. Androst-5-en-17-one, 3-hydroxy-, (3beta)-
41. Epa Pesticide Chemical Code 126510
42. (3beta)-3-hydroxyandrost-5-en-17-one
43. Nsc 9896
44. Nsc-9896
45. Androst-5-en-17-one, 3-hydroxy-, (3.beta.)-
46. Androst-5-en-17-one, 3-beta-hydroxy-
47. Chembl90593
48. (3s,8r,9s,10r,13s,14s)-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one
49. Androst-5-en-17-one, 3-hydroxy-, (3b)-
50. Chebi:28689
51. D5-androsten-3beta-ol-17-one
52. Androst-5-ene-3beta-ol-17-one
53. Nsc9896
54. 459ag36t1b
55. 3beta-hydroxy-d5-androsten-17-one
56. 3-beta-hydroxyandrost-5-en-17-one
57. 3.beta.-hydroxyandrost-5-en-17-one
58. Dsstox_cid_379
59. Dsstox_rid_75553
60. Dsstox_gsid_20379
61. (3s,8r,9s,10r,13s,14s)-3-hydroxy-10,13-dimethyl-3,4,7,8,9,10,11,12,13,14,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17(2h)-one
62. And
63. Prasterone [inn]
64. Prasteronum [inn-latin]
65. Prasterona [inn-spanish]
66. Cas-53-43-0
67. (1s,2r,5s,10r,11s,15s)-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-7-en-14-one
68. Smr000059075
69. Androst-5-en-17-one, 3.beta.-hydroxy-
70. Sr-01000075815
71. Prasterone [usan:inn]
72. Einecs 200-175-5
73. Brn 2058110
74. 5-androsten-3.beta.-ol-17-one
75. Anastar
76. Inflabloc
77. Aslera
78. Unii-459ag36t1b
79. Fidelin T
80. Dhea; Prasterone
81. Ncgc00093802-04
82. Ncgc00093802-06
83. Dehydroepiandosterone
84. Biolaif (tn)
85. Androst-5-en-17-one, 3beta-hydroxy-
86. Dehydroepiandrostenedione
87. 5-dehydro-epiandrosterone
88. Prasterone (usan/inn)
89. Trans-de-hydroandrosterone
90. Prasterone [inci]
91. Prasterone [usan]
92. Bmse000665
93. Ec 200-175-5
94. Prasterone [mart.]
95. Androsten-3beta-ol-17-one
96. Prasterone [who-dd]
97. Androst-5-en-17-one, 3-hydroxy-, (3-beta)-
98. Bidd:pxr0080
99. Lopac0_000368
100. Schembl24156
101. 4-08-00-00994 (beilstein Handbook Reference)
102. Mls001066350
103. Mls001333231
104. Mls001333232
105. Mls001424274
106. 5-androsten-3b-ol-17-one
107. D5-androsten-3b-ol-17-one
108. Gtpl2370
109. Androst-5-ene-3b-ol-17-one
110. Dtxsid4020379
111. Prasterone [orange Book]
112. 3b-hydroxyandrost-5-en-17-one
113. 5-androsten-3-beta-ol-17-one
114. Bcpe00002
115. 3b-hydroxy-d5-androsten-17-one
116. 3beta-hyroxyandrost-5-en-17-one
117. Bcpp000260
118. Dehydroepiandrosterone [mi]
119. El-10
120. Hms2052p11
121. Hms2090c04
122. Hms2232k11
123. Im 28
124. Trans-dehydroandrosterone, >=99%
125. 3-beta-hydroxy-5-androsten-17-on
126. Act02646
127. Amy25708
128. Bcp02453
129. Ipl-1001
130. Zinc3807917
131. 3beta-hydroxy-androst-5-en-17-one
132. 3beta-hydroxyandrost-5-ene-17-one
133. Tox21_111222
134. Tox21_201996
135. Tox21_302761
136. Bdbm50223368
137. Cmc_13435
138. Delta5-androsten-3-beta-ol-17-one
139. Dl-373
140. Gl-701
141. Lmst02020021
142. Pb-007
143. S2604
144. Dehydroepiandrosterone [vandf]
145. 5-androsten-3beta-ol-17-one; Dhea
146. Akos007930299
147. Akos015951378
148. Prasterone 100 Microg/ml In Methanol
149. Tox21_111222_1
150. Bcp9000602
151. Ccg-101190
152. Cs-1667
153. Db01708
154. Fd12003
155. Gs-0906
156. Ip-1001
157. Nc00440
158. Sh-k-04828
159. Ncgc00093802-09
160. Ncgc00256412-01
161. Ncgc00259545-01
162. (1s,5s,11s,15s,2r,10r)-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0<2,7>.0<11,15> ]heptadec-7-en-14-one
163. (3beta)-3-hydroxyandrost-5-ene-17-one
164. Ac-28716
165. Hy-14650
166. Nci60_042215
167. Prasterone (dhea; Dehydroepiandrosterone)
168. (3beta)-3-hydroxy-androst-5-en-17-one
169. D0044
170. Eu-0100368
171. Androst-5-en-17-one, 3beta-hydroxy- (8ci)
172. C01227
173. D 4000
174. D-0340
175. D08409
176. (3alpha,8alpha)-3-hydroxyandrost-5-en-17-one
177. Ab00375810-06
178. Ab00375810_09
179. Q408376
180. Sr-01000075815-1
181. Sr-01000075815-4
182. Brd-k41256143-001-12-7
183. (3beta,16alpha)-3,16-dihydroxy-androst-5-en-17-one
184. Androst-5-en-17-one, 3-hydroxy-, (3beta)- (9ci)
185. Z2213891300
186. 1a9d2040-240c-427d-ade4-0cb700b785cb
187. Prasterone (dhea; Dehydroepiandrosterone) 1.0 Mg/ml In Acetonitrile
188. (3s,8r,10r,13s)-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,10,11,12,13,14,15,16-tetradecahydro-cyclopenta[a]phenanthren-17-one
189. 105597-37-3
190. Dehydroepiandrosterone (dhea) Solution, 1.0 Mg/ml In Methanol, Ampule Of 1 Ml, Certified Reference Material
| Molecular Weight | 288.4 g/mol |
|---|---|
| Molecular Formula | C19H28O2 |
| XLogP3 | 3.2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 0 |
| Exact Mass | 288.208930132 g/mol |
| Monoisotopic Mass | 288.208930132 g/mol |
| Topological Polar Surface Area | 37.3 Ų |
| Heavy Atom Count | 21 |
| Formal Charge | 0 |
| Complexity | 508 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 1 | |
|---|---|
| Drug Name | INTRAROSA |
| Active Ingredient | PRASTERONE |
| Company | AMAG PHARMS INC (Application Number: N208470. Patents: 8268806, 8629129, 8957054) |
DHEA is taken as a supplement for a variety of unsubstantiated indications. The following indications have shown promise and are backed up by some scientific evidence: schizophrenia (DHEA may be more effective in women than men); improving the appearance of older peoples skin (taking DHEA by mouth seems to increase skin thickness and moisture, and decrease facial age spots in elderly men and women); improving ability to achieve an erection in men with sexual dysfunction. Additionally, DHEA has shown promise in improving symptoms of lupus (SLE). Taking DHEA by mouth along with conventional treatment may help reduce the number of times symptoms flare up and may allow a reduction in the dose of prescription drugs needed. DHEA may also help SLE symptoms such as muscle ache and mouth ulcers. DHEA also seems to strengthen bones in SLE patients being treated with high-dose steroids (corticosteroids). DHEA also shows promise in the treatment of osteoporosis. Taking DHEA by mouth daily seems to improve bone mineral density (BMD) in older women and men with osteoporosis or osteopenia (pre-osteoporosis). DHEA may also increase BMD in young women with the eating disorder called anorexia nervosa. DHEA is often prescribed in India for the induction of ovulation to improve chances of pregnancy.
Intrarosa is indicated for the treatment of vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms.
DHEA is naturally produced from cholesterol through two cytochrome P450 enzymes. Cholesterol is converted to pregnenolone by the enzyme P450 scc (side chain cleavage); then another enzyme, CYP17A1, converts pregnenolone to 17-Hydroxypregnenolone and then to DHEA. DHEA is increased by exercise and calorie restriction. Some theorize that the increase in endogenous DHEA brought about by calorie restriction is partially responsible for the longer life expectancy known to be associated with calorie restriction.
Adjuvants, Immunologic
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)
G03XX01
A - Alimentary tract and metabolism
A14 - Anabolic agents for systemic use
A14A - Anabolic steroids
A14AA - Androstan derivatives
A14AA07 - Prasterone
G - Genito urinary system and sex hormones
G03 - Sex hormones and modulators of the genital system
G03X - Other sex hormones and modulators of the genital system
G03XX - Other sex hormones and modulators of the genital system
G03XX01 - Prasterone
Absorption
Following a 50-mg DHEA PO dose in cynomolgus monkeys, systemic availability was only 3.1 +/- 0.4%. [PMID: 12970301]
Hepatic. As shown by their high conversion ratios (in a study involving cynomolgus monkeys), the major circulating metabolites of DHEA are DHEA-S, androsterone glucuronide, and androstane-3 alpha,17 beta-diol-glucuronide. [PMID: 12970301]
Dehydroisoandrosterone has known human metabolites that include 3,16-Dihydroxyandrost-5-en-17-one, 3,7-Dihydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one, and Dehydroisoandrosterone 3-glucuronide.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
12 hours
DHEA can be understood as a prohormone for the sex steroids. DHEAS may be viewed as buffer and reservoir. As most DHEA is produced by the zona reticularis of the adrenal cortex, it is argued that there is a role in the immune and stress response. DHEAS/DHEA are useful to detect excess adrenal activity as seen in adrenal cancer or hyperplasia, including certain forms of congenital adrenal hyperplasia as it is produced nearly entirely by the adrenal glands. Women with polycystic ovary syndrome tend to have elevated levels of DHEAS.
BUILDING BLOCK
SUPPLIERS
CAS Number : 53-43-0
End Use API :
End Use API : Abiraterone Acetate
About the Company : A Swiss chemical company specialized in custom design, development, production & sourcing of specialty chemicals, intermediates and Active Pharmaceutical Ingredients. Driven by technolo...
END USE APIs
RELATED INTERMEDIATES
LOOKING FOR A SUPPLIER?
